On October 15, 2025 Abbott (NYSE: ABT) reported financial results for the third quarter ended Sept. 30, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Third-quarter sales increased 6.9 percent on a reported basis, 5.5 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.
Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.30, which excludes specified items.
Year-to-date sales increased 6.1 percent on a reported basis, 6.4 percent on an organic basis, or 7.7 percent when excluding COVID-19 testing-related sales2.
Abbott reaffirms previously provided full-year 2025 organic sales growth guidance.
Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, reflecting double-digit growth at the midpoint.
In July, Abbott announced it received regulatory approval in Japan for TriClip, a first of-its-kind, minimally invasive treatment option for patients with tricuspid regurgitation, or a leaky tricuspid heart valve.
In August, Abbott announced it received CE Mark for an expanded indication for the company’s Navitor transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery.
In August, at the European Society of Cardiology (ESC) Congress, new treatment guidelines were issued that provide additional support for the use of MitraClip and TriClip in treating valvular heart disease. These new guidelines were backed by evidence from multiple clinical studies.
"Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance," said Robert B. Ford, chairman and chief executive officer, Abbott. "Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders."

THIRD-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Third Quarter 2025 Results (3Q25)

Sales 3Q25 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical
Devices

U.S.

4,299

888

886

—

2,521

International

7,070

1,265

1,367

1,511

2,927

Total reported

11,369

2,153

2,253

1,511

5,448

% Change vs. 3Q24

U.S.

2.3

(6.5)

(14.1)

n/a

13.8

International

9.9

13.3

(1.0)

7.5

15.6

Total reported

6.9

4.2

(6.6)

7.5

14.8

Impact of foreign exchange

1.4

0.2

1.2

0.4

2.3

Organic

5.5

4.0

(7.8)

7.1

12.5

Impact of COVID-19 testing sales 1

(2.0)

—

(8.2)

—

—

Organic (excluding COVID-19 tests)

7.5

4.0

0.4

7.1

12.5

Organic

U.S.

2.3

(6.5)

(14.1)

n/a

13.8

International

7.6

13.0

(3.1)

7.1

11.3

First Nine Months 2025 Results (9M25)

Sales 9M25 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical
Devices

U.S.

12,743

2,800

2,568

—

7,363

International

20,126

3,711

3,912

4,154

8,349

Total reported

32,869

6,511

6,480

4,154

15,712

% Change vs. 9M24

U.S.

6.4

1.4

(7.4)

n/a

14.4

International

6.0

5.3

(3.3)

5.8

11.3

Total reported

6.1

3.6

(5.0)

5.8

12.8

Impact of foreign exchange

(0.3)

(0.9)

(0.2)

(1.7)

0.4

Impact of business exit*

—

(0.2)

—

—

—

Organic

6.4

4.7

(4.8)

7.5

12.4

Impact of COVID-19 testing sales 2

(1.3)

—

(5.4)

—

—

Organic (excluding COVID-19 tests)

7.7

4.7

0.6

7.5

12.4

Organic

U.S.

6.5

1.9

(7.4)

n/a

14.4

International

6.4

6.9

(3.0)

7.5

10.7

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.

*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.

Nutrition

Third Quarter 2025 Results (3Q25)

Sales 3Q25 ($ in millions)

Total

Pediatric

Adult

U.S.

888

520

368

International

1,265

457

808

Total reported

2,153

977

1,176

% Change vs. 3Q24

U.S.

(6.5)

(8.4)

(3.8)

International

13.3

17.9

10.9

Total reported

4.2

2.3

5.8

Impact of foreign exchange

0.2

(0.1)

0.4

Organic

4.0

2.4

5.4

U.S.

(6.5)

(8.4)

(3.8)

International

13.0

18.2

10.2

Worldwide Nutrition sales increased 4.2 percent on a reported basis and 4.0 percent on an organic basis in the third quarter.

Growth in the quarter was led by Adult Nutrition, where sales increased 5.8 percent on a reported basis and 5.4 percent on an organic basis, led by strong growth of Ensure, Abbott’s market-leading complete and balanced nutrition brand, and Glucerna, Abbott’s market-leading brand of products designed to meet the nutritional requirements for people with diabetes.

First Nine Months 2025 Results (9M25)

Sales 9M25 ($ in millions)

Total

Pediatric

Adult

U.S.

2,800

1,695

1,105

International

3,711

1,377

2,334

Total reported

6,511

3,072

3,439

% Change vs. 9M24

U.S.

1.4

3.0

(0.9)

International

5.3

—

8.8

Total reported

3.6

1.6

5.5

Impact of foreign exchange

(0.9)

(0.9)

(0.9)

Impact of business exit*

(0.2)

—

(0.4)

Organic

4.7

2.5

6.8

U.S.

1.9

3.0

0.3

International

6.9

1.8

10.2

*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.

Diagnostics

Third Quarter 2025 Results (3Q25)

Sales 3Q25 ($ in millions)

Total

Core Laboratory

Molecular

Point of Care

Rapid
Diagnostics

U.S.

886

366

36

111

373

International

1,367

998

95

47

227

Total reported

2,253

1,364

131

158

600

% Change vs. 3Q24

U.S.

(14.1)

10.4

(1.5)

7.9

(33.5)

International

(1.0)

1.6

4.3

8.9

(14.2)

Total reported

(6.6)

3.8

2.6

8.2

(27.3)

Impact of foreign exchange

1.2

1.6

1.8

0.4

0.4

Organic

(7.8)

2.2

0.8

7.8

(27.7)

U.S.

(14.1)

10.4

(1.5)

7.9

(33.5)

International

(3.1)

(0.6)

1.7

7.7

(15.6)

Global Diagnostics sales decreased 6.6 percent on a reported basis, decreased 7.8 percent on an organic basis, and increased 0.4 percent when excluding COVID-19 testing-related sales1.

COVID-19 testing-related sales were $69 million in the quarter, compared to $265 million in the third quarter of the prior year.

Global Core Laboratory Diagnostics sales increased 3.8 percent on a reported basis and increased 2.2 percent on an organic basis. Growth in the quarter was impacted by challenging market conditions in China, including the impact of volume-based procurement programs.

First Nine Months 2025 Results (9M25)

Sales 9M25 ($ in millions)

Total

Core Laboratory

Molecular

Point of Care

Rapid
Diagnostics

U.S.

2,568

1,049

111

315

1,093

International

3,912

2,850

265

133

664

Total reported

6,480

3,899

376

448

1,757

% Change vs. 9M24

U.S.

(7.4)

8.3

(0.5)

2.4

(21.2)

International

(3.3)

(1.0)

(2.7)

(0.1)

(12.9)

Total reported

(5.0)

1.3

(2.0)

1.7

(18.2)

Impact of foreign exchange

(0.2)

(0.3)

—

(0.1)

(0.2)

Organic

(4.8)

1.6

(2.0)

1.8

(18.0)

U.S.

(7.4)

8.3

(0.5)

2.4

(21.2)

International

(3.0)

(0.7)

(2.7)

0.3

(12.4)

Established Pharmaceuticals

Third Quarter 2025 Results (3Q25)

Sales 3Q25 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,511

1,097

414

Total reported

1,511

1,097

414

% Change vs. 3Q24

U.S.

n/a

n/a

n/a

International

7.5

10.3

0.6

Total reported

7.5

10.3

0.6

Impact of foreign exchange

0.4

(0.8)

3.1

Organic

7.1

11.1

(2.5)

U.S.

n/a

n/a

n/a

International

7.1

11.1

(2.5)

Established Pharmaceuticals sales increased 7.5 percent on a reported basis and 7.1 percent on an organic basis in the third quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 10.3 percent on a reported basis and 11.1 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East.

First Nine Months 2025 Results (9M25)

Sales 9M25 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

4,154

3,121

1,033

Total reported

4,154

3,121

1,033

% Change vs. 9M24

U.S.

n/a

n/a

n/a

International

5.8

7.3

1.7

Total reported

5.8

7.3

1.7

Impact of foreign exchange

(1.7)

(2.4)

0.5

Organic

7.5

9.7

1.2

U.S.

n/a

n/a

n/a

International

7.5

9.7

1.2

Medical Devices

Third Quarter 2025 Results (3Q25)

Sales 3Q25 ($ in millions)

Total

Rhythm
Management

Electro-

physiology

Heart
Failure

Vascular

Structural
Heart

Neuro-
modulation

Diabetes
Care

U.S.

2,521

350

322

280

280

297

196

796

International

2,927

336

383

86

465

338

58

1,261

Total reported

5,448

686

705

366

745

635

254

2,057

% Change vs. 3Q24

U.S.

13.8

21.1

13.2

10.7

8.5

10.1

3.3

18.4

International

15.6

9.3

17.6

22.6

5.5

16.9

24.9

19.9

Total reported

14.8

15.0

15.6

13.3

6.6

13.6

7.6

19.3

Impact of foreign exchange

2.3

2.0

1.9

1.2

1.9

2.3

0.8

3.1

Organic

12.5

13.0

13.7

12.1

4.7

11.3

6.8

16.2

U.S.

13.8

21.1

13.2

10.7

8.5

10.1

3.3

18.4

International

11.3

5.5

14.1

17.2

2.5

12.4

21.2

14.7

Worldwide Medical Devices sales increased 14.8 percent on a reported basis and 12.5 percent on an organic basis in the third quarter.

Sales growth in the quarter was led by double-digit growth in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure and Structural Heart.

In Diabetes Care, sales of continuous glucose monitors were $2.0 billion and grew 20.5 percent on a reported basis and 17.2 percent on an organic basis.

First Nine Months 2025 Results (9M25)

Sales 9M25 ($ in millions)

Total

Rhythm
Management

Electro-

physiology

Heart
Failure

Vascular

Structural
Heart

Neuro-
modulation

Diabetes
Care

U.S.

7,363

994

943

824

831

868

565

2,338

International

8,349

950

1,091

249

1,381

980

171

3,527

Total reported

15,712

1,944

2,034

1,073

2,212

1,848

736

5,865

% Change vs. 9M24

U.S.

14.4

16.7

12.2

12.4

5.6

14.1

0.3

23.2

International

11.3

3.9

10.9

15.9

4.2

11.8

20.6

15.9

Total reported

12.8

10.1

11.5

13.2

4.7

12.9

4.4

18.7

Impact of foreign exchange

0.4

0.4

0.2

0.3

0.1

0.4

(0.1)

0.6

Organic

12.4

9.7

11.3

12.9

4.6

12.5

4.5

18.1

U.S.

14.4

16.7

12.2

12.4

5.6

14.1

0.3

23.2

International

10.7

3.2

10.5

14.6

4.0

11.2

20.8

14.9

(Press release, Abbott, OCT 15, 2025, View Source [SID1234656667])